ST2 provides new insight on cardiovascular disease progression – relevant disease state information not reflected by other biomarkers and clinical observations.
Multiple published studies by leading investigators from around the world have demonstrated that ST2 is the most prognostic cardiac biomarker available, helping physicians make better treatment decisions than solely relying on clinical parameters and existing laboratory assays.
While BNP and NT-proBNP may help a physician diagnose heart failure in a symptomatic patient, ST2 is most useful in determining the patient’s likely prognosis, regardless of their symptom status. Furthermore, ST2 may help guide physicians on their treatment path : choice of drugs and appropriate dosage, lifestyle changes such as exercise programs, transition to device protocols (cardiac resynchronization therapy (CRT), implantable cardio defibrillators (ICD), ventricular assist devices (VAD), and even prioritization for cardiac transplantation).
The Aspect Plus is a new and easy-to-use lateral flow ST2 test that provides a quantitative result in 20 minutes, allowing for immediate management of heart failure patients requiring customized care and treatment. Continue reading »